Intraoperative vs. Postoperative Intravesical Epirubicin Instillation for Prevention of Bladder Recurrence in High-Risk Upper Urinary Tract Urothelial Carcinoma

Ankara Etlik City Hospital270 enrolled

Overview

Upper urinary tract urothelial carcinoma (UTUC) accounts for 5%-10% of urothelial malignancies, with up to 50% of patients developing bladder recurrence post-RNU. High-risk UTUC (≥pT2, high-grade, or N+ disease) necessitates aggressive management. Intravesical chemotherapy mitigates recurrence risk, yet optimal timing-intraoperative vs. postoperative-remains unclear. This study evaluates intraoperative epirubicin instillation during RNU compared to postoperative administration and no instillation.

Study Type

OBSERVATIONAL

Enrollment

270

Conditions

Bladder Cancer Recurrence Intravesical Instillation Upper Urinary Tract Carcinoma

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * primary high-risk UTUC. Exclusion Criteria: * prior bladder cancer, * low-risk UTUC (managed conservatively), * metastatic disease, * incomplete follow-up

Locations (1)

Ankara City Hospital Bilkent, Ankara, Ankara 06800

Outcomes

Primary Outcomes

To evaluate the relationship between intravesical chemotherapy administered intraoperatively or postoperatively and bladder recurrence.

Time frame: 365 days from the first instillation